HERON THERAPEUTICS, INC. /DE/
Company Stats
- Market Cap
- $59.5M
- as of Sep 30, 2026
- Shares Outstanding
- 189.9M
- Free Float
- 75.7%
Income Statement
- Revenue
- $154.9M
- Operating Income
- -$2.5M
- Net Income
- -$20.2M
- EBITDA
- -$224,000
- Revenue Growth, 3Y
- 12.9%
- FCF Margin, 3Y Avg
- -27.4%
- FCF Margin, Worst Year
- -47.5%
Cash Flow
- Free Cash Flow
- -$27.9M
- FCF Yield
- -46.9%
- Owner FCF Yield
- -64.3%
Balance Sheet
- Cash & Equivalents
- $28.6M
Returns & Capital
- SBC, 3Y Avg
- $18.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $154.9M | -$27.9M | -18.0% |
| FY2024 | $144.3M | -$24.2M | -16.8% |
| FY2023 | $127.0M | -$60.3M | -47.5% |
| FY2022 | $107.7M | -$148.7M | -138.1% |
| FY2021 | $86.3M | -$206.4M | -239.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 22, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Heron Agrees to Sell Assets to CorMedix
Stronger demand supports expansion as pricing diverges